Gilead Sciences, Inc. (GILD) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Foster City, CA, United States. El CEO actual es Daniel O'Day.
GILD tiene fecha de IPO 1992-01-22, 17,600 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $174.33B.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes innovative medicines addressing unmet medical needs across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic areas, including HIV/AIDS treatment with leading antiretroviral products such as Biktarvy and Truvada, hepatitis C and liver disease management through Epclusa and Harvoni, oncology and cell therapy with products like Yescarta and Trodelvy, and other critical care areas including pulmonary arterial hypertension and serious fungal infections. Gilead also gained prominence for Veklury, its antiviral treatment for COVID-19. The company maintains strategic collaboration agreements with numerous leading biopharmaceutical and research organizations to advance its pipeline and expand its therapeutic capabilities.
